Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies

被引：0

作者：

Sagedal, S

Hartmann, A

机构：

[1] Univ Oslo, Rikshosp, Dept Internal Med, N-0027 Oslo, Norway

[2] Univ Oslo, Rikshosp, Lab Renal Physiol, N-0027 Oslo, Norway

来源：

EUROPEAN JOURNAL OF MEDICAL RESEARCH | 2004年 / 9卷 / 03期

关键词：

low molecular weight heparin; dalteparin; nadroparin; enoxaparin; tinzaparin; reviparin; logiparin; parnaparin; ardeparin; berniparin; hemodialysis; hemofiltration; hemodiafiltration; continuous renal replacement therapy;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Low molecular weight heparins (LMWHs) have potential advantages over unfractionated hep-arin (UFH). They interact less with platelets and may induce less bleeding. The risk for heparin induced thrombocytopenia is less, and the effect on serum lipids is favourable. The half-life is longer, allowing for one single bolus dose at start of hemo-dialysis (HD). In addition, LMWH is found to result in lower plasma potassium in HD patients compared to UFH. LMWHs have an established role in HD and he-mofiltration (HF), but the reports on their efficacy and safety during continuous renal replacement therapy (CRRT) are scarce.

引用

页码：125 / 130

页数：6

共 45 条

[1]

ANASTASSIADES E, 1989, CLIN NEPHROL, V32, P290

[2] A LOW-MOLECULAR-WEIGHT HEPARIN (KABI 2165, FRAGMIN) IN REPEATED USE FOR HEMODIALYSIS - PREVENTION OF CLOTTING AND PROLONGATION OF THE VENOUS COMPRESSION TIME IN COMPARISON WITH COMMERCIAL UNFRACTIONATED HEPARIN [J].